Pursuit NW Stands United for Israel

Pro-Israel March
Interfaith Rally

SEATTLE, May 8, 2024 (Newswire.com)
–
The Pursuit NW, under the leadership of Pastor Russell Johnson, is proud to announce its continued commitment to advocating for Israel with the upcoming “United for Israel” rally at the University of Washington on Sunday, May 12th, 2024, at 4:30 p.m. The rally will start at Red Square, with a march through the campus and will conclude at the Pursuit Seattle campus located on UW’s frat row.

Pastor Russell spearheaded the impactful University of Washington march, which convened shortly after the October 7th attacks on Israel. The Seattle event, in collaboration with StandWithUs and Oregon for Israel, featured distinguished guest speaker Mosab Hassan Yousef, renowned for his courageous stance as the “Son of Hamas.”

He went on to direct the recent Pro-Israel rallies at Columbia University and the University of Southern California in collaboration with Sean Feucht, Let Us Worship, Hold the Line, StandWithUs, and various Jewish and Christian groups. The resoundingly successful events drew thousands of attendees representing various faiths. Since the events, the organization has been inundated with requests for similar initiatives to counter the alarming rise of antisemitism on college campuses across America.

Pastor Russell brings a wealth of experience and passion to Pro-Israel initiatives and is excited to return to his home base in Seattle, where the initiative first came to fruition. The Pursuit aims to provide a platform for the majority voice in America amidst media portrayals influenced by minority extremist perspectives. Pastor Johnson emphasizes the rally’s focus on essential issues, including Israel’s right to self-defense, the immediate release of all remaining hostages, and the restoration of lasting peace in the region.

About:

The Pursuit, based in Washington state, is a non-denominational church across multiple campuses, including Seattle, Kirkland, Snohomish, and an online presence. The church’s mission centers on glorifying Jesus and bringing people into an encounter with the presence of God. It’s no coincidence that their Seattle Campus is on the University of Washington’s Frat Row.

Contact: 

Pursuit NW Church | 9051 132nd Ave NE, Kirkland, WA. 98033

Emma LaMarche | [email protected]

Media Intake Coordinator | 425-205-7428 | www.thepursuitnw.com

Contact Information:

Emma LaMarche

Media Intake Coordinator

[email protected]

425-205-7428

Original Source:

Pursuit Church Announces ‘United for Israel’ Rally at the University of Washington

The post Pursuit Church Announces ‘United for Israel’ Rally at the University of Washington first appeared on RSVTV news.

Kids Email Logo

ROCKVILLE, Utah & ARBON, Idaho, May 8, 2024 (Newswire.com)
–
Jacob Andersen, the founder of KidsEmail.org, a leading child safety platf…

The post KidsEmail.org Acquired by Internet Safety Expert JT Smith in Strategic Move to Enhance Child Digital Safety first appeared on RSVTV news.

Freyja Healthcare Brings First-of-Its-Kind 2mm Abdominal-Access Device to Laparoscopic Surgery to Further Innovation in Fast-Growing Women’s Health Market

BOSTON, May 8, 2024 (Newswire.com)
–
Freyja Healthcare, an early-stage medical device company focused on developing a robust product portfolio of highly innovative products for women’s health, today announced that its novel VereSee device received 510(k) clearance from the United States Food and Drug Administration (FDA). Clearance from the FDA marks a critical step in enabling Freyja and VereSee — the first and only 2mm, safe abdominal-access video-entry device for laparoscopic surgery — to bring further innovation in the fast-growing women’s health market.  VereSee will reinvigorate a category that has not seen innovation in over three decades.

Founded by Jón Ívar Einarsson, MD, PhD, MPH, and Gaby Moawad, MD, FACOG, Freyja’s mission is to raise the standard of women’s health in both surgical and in-office procedures, enabling physicians to deliver safe and effective care. As the company’s first novel product, the VereSee device features a proprietary design engineered to be simple for the surgeon, safe for the patient, and highly differentiated from the current standard of care. The company now has four products in advanced stages of development, 17 granted patents and 21 pending patents.

“From the beginning, I’ve been impressed with Freyja’s mission to improve gynecologic solutions for women and the providers who take care of them. With this first product, Freyja is bringing  meaningful innovation to a category ready for change,” said Kim Rodriguez, longtime Freyja Executive Chairman and former CEO of Acessa Health. 

There are 4.8 million laparoscopic surgeries performed annually in the United States. Abdominal entry is the most dangerous step of laparoscopic and robotic surgery in women’s health, and in all laparoscopic surgery across all specialty areas. This dangerous step results in one patient death and eight injuries in the U.S. each day^[1].

“The standard of care is dangerous and outdated. Initial entry is often done blindly with Veres needles or a 5-12mm optical trocar,” said Jón Ívar Einarsson, MD, co-founder and interim CEO of Freyja. “Damaging the bowel or vasculature because of blind entry can cause significant harm, even death, if undetected.” 

As a part of the FDA clearance process, Freyja performed extensive testing and documentation of the safety and efficacy of the product, validating the company’s confidence in the design of its VereSee product. 

“FDA clearance has been a long process for us, and we know that this is one of the largest barriers to entry for new products in this category,” said Gaby Moawad, MD, co-founder and Board Director of Freyja. “However, we understand the importance of these devices being held to the highest standards of safety and quality. We are proud of the work our team has done to reach this milestone for Freyja.”

Freyja will soon begin initial commercialization of the VereSee device, with broad availability expected in the second half of 2024.

About Freyja Healthcare 

Freyja Healthcare was founded in 2017, has four products in advanced stages of development, 17 granted patents and 21 pending patents, and is engineering a robust product portfolio focused on safe and effective surgical and in-office solutions for women. Founded by two well-respected, minimally invasive gynecologic surgeons, Jón Ívar Einarsson, MD, PhD, MPH, Past-President of AAGL, founder of the Division of Minimally Invasive Gynecologic Surgery (MIGS) at Brigham and Women’s Hospital (BWH) and a Professor of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School, and Gaby Moawad, MD, FACOG, Associate Professor of Obstetrics and Gynecology at The George Washington University School of Medicine and Health Sciences (GWSMHS). Drs. Einarsson and Moawad are inventing and building the products they wish they had early in their careers and elevating the standards for products used in women’s health surgical and in-office care. Freyja has raised almost $8 million in seed funding from private and professional high net-worth investors. Learn more at Freyja Healthcare.

^[1] Clark NV, Einarsson JI. Laparoscopic entry techniques. In: Minimally invasive surgery in gynecologic practice. De Gruyter 2020.

Contact Information:

Jerry Brecher

[email protected]

Original Source:

Freyja HealthCare’s VereSee™ Device Receives 510(k) Clearance, the First of Many Products

The post Freyja HealthCare’s VereSee™ Device Receives 510(k) Clearance, the First of Many Products first appeared on RSVTV news.

Announcement Coincides with Major Marijuana Reclassification Announcements from The White House Administration

Kushi Labs, Inc. Logo
Kushi Labs, Inc. Logo

DENVER, May 8, 2024 (Newswire.com)
–
In response to growing consumer demand, Clear Cannabis, Inc. (CCI), a leader in cannabis innovation and quality since 2013, is thrilled to announce the expansion of its popular brand, The CLEAR^TM to New Jersey through a strategic partnership with Kushi Labs. This collaboration marks a significant milestone as the company introduces its top-tier cannabis products to The Garden State. This marks the 12th state for The Clear and its market expansion. 

Under this agreement, CCI will license its IP formulas, processes, and operational knowledge to Kushi Labs. 

“The CLEAR has consistently set the benchmark for excellence and innovation in the cannabis market,” said Richard M. Batenburg, Jr., CEO of Clear Cannabis, Inc. “Our decision to bring The CLEAR to New Jersey with Kushi Labs is a testament to our commitment to meet consumer demand and deliver unparalleled cannabis experiences.”

The CLEAR’s products are celebrated for their unparalleled purity, potency, and palate-pleasing flavors, setting the industry standard for cannabis product excellence. 

This expansion into New Jersey is driven by a strong market demand and a commitment to making these superior products more accessible to discerning consumers in more states. 

Kushi Labs, known in the New Jersey cannabis sector for its exceptional manufacturing processes, will serve as the licensed partner, ensuring that the same high-quality standards known across the U.S. are upheld. The CLEAR’s entry into New Jersey is anticipated to set new benchmarks in the market for product quality and consumer satisfaction.

“Our partnership with Clear Cannabis, Inc. represents a pivotal development in our mission to offer the best cannabis products to New Jersey residents,” stated Ajay Patel, CEO of Kushi Labs. “The CLEAR’s reputation for quality and trust makes them the ideal partner for us as we look to elevate the cannabis experience in our state.”

This expansion into New Jersey coincides with the Biden administration’s recent announcement to reclassify marijuana as a class-3 drug, easing restrictions on its use and research.

“The reclassification of marijuana by the White House is a significant step towards greater acceptance and accessibility of cannabis products, and The CLEAR is proud to be at the forefront of this movement,” said Batenburg.

About The Clear Cannabis, Inc.:

Since its inception in 2013, The CLEAR (part of Clear Cannabis, Inc.) has been at the innovation forefront of the cannabis industry, offering a diverse range of products from vapes to edibles, pre-rolled joints and more. Known for its exceptional flavors and consistent quality, The CLEAR has become one of the most trusted and awarded cannabis brands in the United States. 

From Mild to Wild and Everything Between, The CLEAR has something for everyone, catering to a wide array of lifestyles and preferences, ensuring a premium experience to be enjoyed by all.

For additional information about Clear Cannabis, Inc. and The CLEAR, please visit https://clearcannabisinc.com/.

About Kushi Labs: 

Founded in 2021, Kushi Labs is a leading Licensed Cannabis Manufacturing facility in New Jersey. Dedicated to becoming the primary supplier for cultivators and dispensaries statewide, the company emphasizes innovation and excellence. By integrating advanced technology, Kushi Labs sets high standards in cannabis manufacturing quality and efficiency. Supported by a diverse team of engineers, scientists, businessmen, and connoisseurs, all united by their passion, Kushi Labs commits to delivering outstanding products and services as an industry leader. 

Contact Information:

Brett Schklar

CMO

[email protected]

3038832449

Related Images

Kushi Labs, Inc. Logo

Kushi Labs, Inc. Logo

The CLEAR Logo

The CLEAR Logo

Original Source:

Clear Cannabis, Inc. Expands ‘The Clear’ Brand in New Jersey With Kushi Labs

The post Clear Cannabis, Inc. Expands ‘The Clear’ Brand in New Jersey With Kushi Labs first appeared on RSVTV news.